Projects per year
Personal profile
Biography
Professor Mark Shackleton is the Group Leader, Cancer Development and Treatment Laboratory, in the School of Translational Medicine at Monash University, Professor of Oncology in the Department of Medicine, at Monash Univerisity, and the Director of Oncology at Alfred Health.
Department of Medicine (Alfred) Research Laboratories - Shackleton Group
After training in medical oncology and at the Ludwig Institute in Melbourne, Prof Shackleton undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA, with resultant publications in Nature, Cell, Cancer Cell and the New England Journal of Medicine. He was awarded the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, a 2011 Pfizer Australia Fellowship, and in 2012 received the Australian Science Minister’s Prize for Life Scientist of the Year.
Most recently a Medical Oncologist and Head of the Cancer Development and Treatment Laboratory at the Peter MacCallum Cancer Centre, Prof Shackleton’s main clinical interests are centred on patients diagnosed with skin cancer, including melanoma. His research interests include cancer biology, developmental biology, oncogenic signaling pathways and clinical trials.
Education/Academic qualification
PhD, Walter and Eliza Hall Institute of Medical Research (WEHI)
2001 → 2006
External positions
Co-Director, Monash Partners Comprehensive Cancer Consortium (MPCCC)
2023 → …
Director of Oncology, Alfred Health
2017 → …
Research area keywords
- Melanoma
- Cancer Therapeutics
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
-
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
Shackleton, M. (Primary Chief Investigator (PCI))
9/05/26 → 1/03/30
Project: Research
-
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-Metastatic Uveal Melanoma (OPTIMUM-10)
Shackleton, M. (Primary Chief Investigator (PCI))
13/03/26 → 12/03/28
Project: Research
-
Why do proteins mimic the repressive mark H3K27me3?
Davidovich, C. (Primary Chief Investigator (PCI)), Shackleton, M. (Associate Investigator (AI)), McGlinn, E. (Associate Investigator (AI)) & Healy, E. (Associate Investigator (AI))
1/01/26 → 31/12/29
Project: Research
-
TRIUMPH: TRIUMPH – Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Ameratunga, M. (Primary Chief Investigator (PCI)) & Shackleton, M. (Supervisor)
1/08/25 → 31/07/27
Project: Research
-
The ACRF Centre for Dynamic Immuno-Oncology (CDIO)
Shackleton, M. (Primary Chief Investigator (PCI)), Cherk, M. (Chief Investigator (CI)), Naranbhai, V. (Chief Investigator (CI)), McLean, C. (Chief Investigator (CI)), Monif, M. (Chief Investigator (CI)), Si Lun Tam, C. (Chief Investigator (CI)), Kalff, A. (Chief Investigator (CI)), Fleming, S. (Chief Investigator (CI)), Mar, V. (Chief Investigator (CI)), Ge, Z. (Chief Investigator (CI)) & Cheung, J. (Project Manager)
7/04/25 → 7/01/30
Project: Research
-
Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review
Zaman, F. Y. (Leading Author), Ghaus, A., Shackleton, M., Kee, D., Joshua, A. M., O'Day, R. & Ameratunga, M. (Leading Author), Jan 2026, In: Clinical & Experimental Ophthalmology. 54, 1, p. 99-112 14 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Expansion of a circulating Ki67-positive effector T-cell population following combined PD-1 and CTLA-4 blockade for melanoma is predictive of treatment response
Edwards, J. M., Senthi, S., Smith, R., Burridge, H., Owens, C., Shackleton, M., Andrews, M. C. & van Zelm, M. C., 9 Oct 2025, In: Journal for ImmunoTherapy of Cancer. 13, 10, 14 p., e012317.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Link opens in a new tab Citation (Scopus) -
Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation
Fedele, C., Kuser-Abali, G., Rossi, R., Zhao, P., Li, J., Ameratunga, M., Szeto, P., Zhang, Y. F., Andrews, M. & Shackleton, M., Jul 2025, In: Pigment Cell and Melanoma Research. 38, 4, 18 p., e70011.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin
Ugalde, A., Tothill, R. W., Quinn, S., Wong, H. L., Prall, O., Mitchell, C., Wickramasinghe, N., Fedele, C., Richards, N., Todio, E., Bryant, C., Collins, L. G., McLean, S., Ko, H. S., Akhurst, T., Steer, C., Gao, B., Wong, M., Georgiou, C. & Karanth, N. & 12 others, , 29 Jan 2025, In: BMC Cancer. 25, 1, 11 p., 171.Research output: Contribution to journal › Article › Other › peer-review
Open Access1 Link opens in a new tab Citation (Scopus) -
Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases
Walpole, I., Zaman, F. Y., Zhao, P., Marshall, V., Lin, F., Thomas, D. M., Shackleton, M., Antolin, A. & Ameratunga, M., Apr 2024, In: Clinical and Translational Medicine. 14, 4, 15 p., e1657.Research output: Contribution to journal › Article › Research › peer-review
Open Access
-
Member
Shackleton, M. (Member)
2023 → …Activity: External Academic Engagement › Committees and working groups
-
Member
Shackleton, M. (Member)
2023 → …Activity: External Academic Engagement › Committees and working groups
-
Member
Shackleton, M. (Member)
2023 → …Activity: External Academic Engagement › Committees and working groups
-
Member
Shackleton, M. (Member)
2023 → …Activity: External Academic Engagement › Committees and working groups
-
Member
Shackleton, M. (Member)
2023 → …Activity: External Academic Engagement › Committees and working groups
Press/Media
-
TV recorded interview re: Paula Fox Melanoma and Cancer Centre, Channel 9
1/06/23
1 Media contribution
Press/Media: Profile/Interview
-
TV recorded interview re: melanoma sequencing study, Channel 10
1/03/21
1 Media contribution
Press/Media: Profile/Interview
-
The Herald Sun re: melanoma autopsy sequencing study
1/01/21
1 Media contribution
Press/Media: Article/Feature
-
Radio live interview with Red Symons (ABC Breakfast) re: melanoma research
1/08/15
1 Media contribution
Press/Media: Profile/Interview
-
Radio recorded interview for ABC Nationwide AM re: melanoma research
1/08/15
1 Media contribution
Press/Media: Profile/Interview